mProX™ Human TEK Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Caki-1;ACHN

Target Classification

Kinase Cell Lines

Target Research Area

Cardiovascular Research

Related Diseases

Venous Malformations, Multiple Cutaneous And Mucosal; Glaucoma 3, Primary Congenital, E

Gene ID

Human:7010

UniProt ID

Human:Q02763

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TEK, also known as TIE2, is a receptor tyrosine kinase that plays a vital role in angiogenesis, the process of new blood vessel formation. In scientific research, TEK has been extensively studied for its role in vascular development and homeostasis. Mutations in the TEK gene have been linked to various vascular anomalies, underscoring its significance in vascular biology. Furthermore, the TEK signaling pathway has been implicated in cancer progression, particularly in the context of tumor angiogenesis. The ability of tumors to form new blood vessels is crucial for their growth and metastasis, making TEK a potential therapeutic target in oncology. The receptor's involvement in both physiological and pathological angiogenesis highlights its importance in vascular biology and its potential as a therapeutic target.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human TEK Stable Cell Line (S01YF-1023-PY114). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Smith (Verified Customer)

What is the role of TEK in clear cell renal cell carcinoma? Jul 04 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TEK inhibits the development of clear cell renal cell carcinoma by regulating AKT phosphorylation and promoting apoptosis. Jul 04 2020

chat Alex Williams (Verified Customer)

How does TEK affect breast cancer metastasis? Sep 28 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

TEK, in conjunction with SIRT7, can promote adriamycin-induced metastasis in breast cancer. Sep 28 2021

Published Data

Fig.1 Enhanced cell proliferation was observed in ccRCC cells following the knockdown of TEK.

The efficacy of TEK-siRNA silencing on protein levels was verified in ACHN and Caki-1 cells, and the effect of TEK silencing on cloning formation ability was assessed through the cloning formation assay.

Ref: Chen, Siming, et al. "The immune-related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation." Cancer Cell International 21 (2021): 1-14.

Pubmed: 33602230

DOI: 10.1186/s12935-021-01830-1

Research Highlights

Musayev, Ogtay. et al. "Could Heart Rate Variability Serve as a Prognostic Factor in Patients with Pulmonary Hypertension? A Single-center Pilot Study." Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2023.
This study investigated the impact of heart rate variability (HRV) on short-term prognosis in individuals with pulmonary hypertension (PH). HRV, a measure of cardiac autonomic tone, is characterized by periodic fluctuations in sinus rate over time. The aim of this study was to determine whether HRV could be used as a predictor of short-term outcomes in PH patients. Findings suggest that HRV may be a useful tool for assessing cardiac function and predicting prognosis in those with PH.
Musayev, Ogtay. et al. "Could Heart Rate Variability Serve as a Prognostic Factor in Patients with Pulmonary Hypertension? A Single-center Pilot Study." Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2023.
Pubmed: 37861265 DOI: 10.5543/tkda.2023.27078

Yağmur, Burcu. et al. "Long-Term Natural Course of Patients with Pulmonary Artery Pressures in the Range of 21-24 mmHg: Insights from a Single-Center Study." Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2023.
In a retrospective study spanning 2008 to 2021, patients with moderate-to-high echocardiographic risk who underwent right heart catheterization (RHC) were followed for at least one year to investigate the long-term outlook of individuals with mean pulmonary artery pressure (mPAP) values between 21 and 24 mmHg, previously categorized as "borderline pulmonary hypertension (PH)." Among the 140 patients analyzed (mean age 53.1 ± 14.8 years, female 74.5%) from a total of 395 diagnostic RHCs, those with mPAP <21 mmHg exhibited better NT-pro-BNP levels and 6-min walking distances, whereas echocardiographic findings indicative of PH were more prevalent in the mPAP 21-24 mmHg group. Furthermore, individuals with mPAP 21-24 mmHg showed significantly worse pulmonary artery wedge pressure and cardiac index values. While all-cause mortality tended to be higher in the borderline PH group during the up to 13-year follow-up, this difference did not achieve statistical significance. This single-center observational study suggests that patients with an mPAP of 21-24 mmHg may face a more unfavorable prognosis compared to those with mPAP values below 21 mmHg over the extended follow-up period.
Yağmur, Burcu. et al. "Long-Term Natural Course of Patients with Pulmonary Artery Pressures in the Range of 21-24 mmHg: Insights from a Single-Center Study." Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2023.
Pubmed: 37861260 DOI: 10.5543/tkda.2023.65724